190 related articles for article (PubMed ID: 37182595)
1. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
[TBL] [Abstract][Full Text] [Related]
4. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
6. High hydrostatic pressure induces atrial electrical remodeling through angiotensin upregulation mediating FAK/Src pathway activation.
Li X; Deng CY; Xue YM; Yang H; Wei W; Liu FZ; Guo HM; Liu Y; Wang ZY; Zhang MZ; Wu SL; Rao F
J Mol Cell Cardiol; 2020 Mar; 140():10-21. PubMed ID: 32006532
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
[TBL] [Abstract][Full Text] [Related]
8. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients.
Yang L; Zhang M; Hao Z; Wang N; Zhang M
ESC Heart Fail; 2022 Aug; 9(4):2428-2434. PubMed ID: 35437929
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
12. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
Li SN; Zhang JR; Zhou L; Xi H; Li CY; Zhao L
J Cardiovasc Transl Res; 2022 Feb; 15(1):131-142. PubMed ID: 34075552
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
[TBL] [Abstract][Full Text] [Related]
16. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
17. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
18. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]